Natco Pharma today announced the launch of the first generic version of Sofosbuvir 400mg/Velpatasvir 100 mg fixed dose combination in Nepal. Sofosbuvir 400mg/Velpatasvir 100 mg fixed dose combination is sold by Gilead Sciences, Inc., under the brandname Epclusa®. Epclusa® is the first all-oral, pan-genotypic, single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection.

Epclusa is also the first single tablet regimen approved for the treatment of patients with HCV genotype 2 and 3, without the need for Ribavirin. Natco will market Sofosbuvir 400mg/Velpatasvir 100mg under the brand name VELPANAT.

The Hyderabad-based firm has priced its generic medicine of ‘Velpanat’ at ₹25,000 equivalent for a bottle of 28 tablets in Nepal. Natco has signed a non-exclusive licensing agreement with Gilead Sciences to manufacture and sell generic versions of its Hep C medicines in 101 developing countries.

comment COMMENT NOW